This approach could be combined with treatments with CCL2 blocking antibody and the anti-leptin signaling peptide in obese tumor-bearing mice, aiming to inhibit macrophage recruitment/activity in the mammary tumor microenvironment. Here, CCL2 is linked to breast cancer.